Telomir Pharmaceuticals announces new findings in prostate cancer model

Telomir Pharmaceuticals (TELO) announced new preclinical results showing that its investigational therapy Telomir-1 reactivated two of the body’s most important tumor suppressor genes, MASPIN and RASSF1A, through DNA methylation reset in prostate cancer models. By restoring the activity of these genes, Telomir-1 may help prevent cancer spread and improve chemotherapy response. Key New Findings: MASPIN: MASPIN is a natural defense protein that blocks tumor invasion, regulates cell migration and angiogenesis, promotes apoptosis, and enhances treatment sensitivity. In an aggressive prostate-cancer model in vivo, MASPIN was silenced by DNA hypermethylation. Telomir-1 reversed the chemotherapy-induced DNA methylation to restore MASPIN activity, consistent with reactivation of this key tumor-suppressor pathway. RASSF1A: RASSF1A is a critical regulator of cell cycle brakes, apoptosis, and suppression of metastasis. It is commonly silenced in aggressive cancers by hypermethylation. Telomir-1 reduced RASSF1A methylation in a dose-dependent manner, with stronger effects when combined with chemotherapy. Implication: These results suggest Telomir-1 may reactivate natural tumor defenses, counteract chemotherapy-induced resistance mechanisms, and help limit metastasis – two of the most persistent challenges in oncology. Telomir is advancing Telomir-1 through preclinical development and IND-enabling studies. Additional evaluations are underway in prostate cancer and other aggressive tumor models where epigenetic silencing and metabolic dysfunction drive metastasis and treatment resistance.